Literature DB >> 31747516

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.

Haibin Zhou, Longchuan Bai, Renqi Xu, Yujun Zhao, Jianyong Chen, Donna McEachern, Krishnapriya Chinnaswamy, Bo Wen, Lipeng Dai, Praveen Kumar, Chao-Yie Yang, Zhaomin Liu, Mi Wang, Liu Liu, Jennifer L Meagher, Han Yi, Duxin Sun, Jeanne A Stuckey, Shaomeng Wang.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases. Despite 20 years of persistent research efforts, targeting STAT3 has been very challenging. We report herein the structure-based discovery of potent small-molecule STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept. We first designed SI-109 as a potent, small-molecule inhibitor of the STAT3 SH2 domain. Employing ligands for cereblon/cullin 4A E3 ligase and SI-109, we obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36. SD-36 induces rapid STAT3 degradation at low nanomolar concentrations in cells and fails to degrade other STAT proteins. SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3. A single dose of SD-36 results in complete STAT3 protein degradation in xenograft tumor tissue and normal mouse tissues. SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules. SD-36 is a potent, selective, and efficacious STAT3 degrader.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31747516      PMCID: PMC8848307          DOI: 10.1021/acs.jmedchem.9b01530

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

Review 1.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 2.  Small-Molecule PROTACS: New Approaches to Protein Degradation.

Authors:  Momar Toure; Craig M Crews
Journal:  Angew Chem Int Ed Engl       Date:  2016-01-12       Impact factor: 15.336

3.  Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.

Authors:  Pijus K Mandal; Donald Limbrick; David R Coleman; Garrett A Dyer; Zhiyong Ren; J Sanderson Birtwistle; Chiyi Xiong; Xiaomin Chen; James M Briggs; John S McMurray
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

Review 4.  Targeted Protein Degradation by Small Molecules.

Authors:  Daniel P Bondeson; Craig M Crews
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-10-12       Impact factor: 13.820

5.  Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.

Authors:  Pijus K Mandal; Fengqin Gao; Zhen Lu; Zhiyong Ren; Rajagopal Ramesh; J Sanderson Birtwistle; Kumaralal K Kaluarachchi; Xiaomin Chen; Robert C Bast; Warren S Liao; John S McMurray
Journal:  J Med Chem       Date:  2011-04-26       Impact factor: 7.446

6.  Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.

Authors:  Jing Lu; Yimin Qian; Martha Altieri; Hanqing Dong; Jing Wang; Kanak Raina; John Hines; James D Winkler; Andrew P Crew; Kevin Coleman; Craig M Crews
Journal:  Chem Biol       Date:  2015-06-04

7.  Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.

Authors:  Chong Qin; Yang Hu; Bing Zhou; Ester Fernandez-Salas; Chao-Yie Yang; Liu Liu; Donna McEachern; Sally Przybranowski; Mi Wang; Jeanne Stuckey; Jennifer Meagher; Longchuan Bai; Zhuo Chen; Mei Lin; Jiuling Yang; Danya N Ziazadeh; Fuming Xu; Jiantao Hu; Weiguo Xiang; Liyue Huang; Siwei Li; Bo Wen; Duxin Sun; Shaomeng Wang
Journal:  J Med Chem       Date:  2018-07-18       Impact factor: 7.446

Review 8.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

Review 9.  Phosphotyrosyl mimetics in the development of signal transduction inhibitors.

Authors:  Terrence R Burke; Kyeong Lee
Journal:  Acc Chem Res       Date:  2003-06       Impact factor: 22.384

10.  IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding.

Authors:  R Z Cer; U Mudunuri; R Stephens; F J Lebeda
Journal:  Nucleic Acids Res       Date:  2009-04-24       Impact factor: 16.971

View more
  37 in total

1.  DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.

Authors:  Rahul S Bhansali; Malini Rammohan; Paul Lee; Anouchka P Laurent; Qiang Wen; Praveen Suraneni; Bon Ham Yip; Yi-Chien Tsai; Silvia Jenni; Beat Bornhauser; Aurélie Siret; Corinne Fruit; Alexandra Pacheco-Benichou; Ethan Harris; Thierry Besson; Benjamin J Thompson; Young Ah Goo; Nobuko Hijiya; Maria Vilenchik; Shai Izraeli; Jean-Pierre Bourquin; Sébastien Malinge; John D Crispino
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

2.  Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.

Authors:  Maha Hanafi; Xinde Chen; Nouri Neamati
Journal:  J Med Chem       Date:  2021-01-28       Impact factor: 7.446

Review 3.  Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy.

Authors:  Lixia Chen; Xinqiang Wan; Xiangxiang Shan; Wenzhang Zha; Rengen Fan
Journal:  Mol Diagn Ther       Date:  2022-04-26       Impact factor: 4.074

4.  PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.

Authors:  Xin Han; Wenyi Wei; Yi Sun
Journal:  Acta Mater Med       Date:  2022-05-31

5.  Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity.

Authors:  Xuan Zhang; Dinesh Thummuri; Xingui Liu; Wanyi Hu; Peiyi Zhang; Sajid Khan; Yaxia Yuan; Daohong Zhou; Guangrong Zheng
Journal:  Eur J Med Chem       Date:  2020-02-27       Impact factor: 6.514

Review 6.  PROTACs to address the challenges facing small molecule inhibitors.

Authors:  Pedro Martín-Acosta; Xiangshu Xiao
Journal:  Eur J Med Chem       Date:  2020-11-05       Impact factor: 6.514

7.  AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.

Authors:  Santanu Hati; Marisa Zallocchi; Robert Hazlitt; Yuju Li; Sarath Vijayakumar; Jaeki Min; Zoran Rankovic; Sándor Lovas; Jian Zuo
Journal:  Eur J Med Chem       Date:  2021-09-20       Impact factor: 6.514

8.  Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.

Authors:  Yunchao Chang; Jaeki Min; Jamie A Jarusiewicz; Marisa Actis; Shanshan Yu-Chen Bradford; Anand Mayasundari; Lei Yang; Divyabharathi Chepyala; Lisa J Alcock; Kathryn G Roberts; Stanley Nithianantham; Dylan Maxwell; Lauren Rowland; Randolph Larsen; Aman Seth; Hiroaki Goto; Toshihiko Imamura; Koshi Akahane; Baranda S Hansen; Shondra M Pruett-Miller; Elisabeth M Paietta; Mark R Litzow; Chunxu Qu; Jun J Yang; Marcus Fischer; Zoran Rankovic; Charles G Mullighan
Journal:  Blood       Date:  2021-12-09       Impact factor: 25.476

Review 9.  Targeting NRF2 to treat cancer.

Authors:  Jared Sivinski; Donna D Zhang; Eli Chapman
Journal:  Semin Cancer Biol       Date:  2021-06-05       Impact factor: 15.707

10.  Novel Target Opportunities in Non-Metastatic Castrate Resistant Prostate Cancer.

Authors:  Stephanie Gleicher; Baylee A Porter; Disharee Nath; Guanqun Li; Rakesh Khanna; Hanan Goldberg; Marcin Kortylewski; Gennady Bratslavsky; Leszek Kotula
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.